- Home
- MODD vs IMMX Comparison
MODD vs IMMX Comparison
Compare MODD & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- IMMX
- Stock Information
- Founded
- MODD 1998
- IMMX 2014
- Country
- MODD United States
- IMMX United States
- Employees
- MODD N/A
- IMMX N/A
- Industry
- MODD Industrial Specialties
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- MODD Health Care
- IMMX Health Care
- Exchange
- MODD Nasdaq
- IMMX Nasdaq
- Market Cap
- MODD 55.3M
- IMMX 50.1M
- IPO Year
- MODD N/A
- IMMX 2021
- Fundamental
- Price
- MODD $1.00
- IMMX $2.09
- Analyst Decision
- MODD
- IMMX Strong Buy
- Analyst Count
- MODD 0
- IMMX 1
- Target Price
- MODD N/A
- IMMX $7.00
- AVG Volume (30 Days)
- MODD 95.0K
- IMMX 59.2K
- Earning Date
- MODD 06-20-2025
- IMMX 05-20-2025
- Dividend Yield
- MODD N/A
- IMMX N/A
- EPS Growth
- MODD N/A
- IMMX N/A
- EPS
- MODD N/A
- IMMX N/A
- Revenue
- MODD N/A
- IMMX N/A
- Revenue This Year
- MODD N/A
- IMMX N/A
- Revenue Next Year
- MODD N/A
- IMMX N/A
- P/E Ratio
- MODD N/A
- IMMX N/A
- Revenue Growth
- MODD N/A
- IMMX N/A
- 52 Week Low
- MODD $0.68
- IMMX $1.26
- 52 Week High
- MODD $2.65
- IMMX $2.71
- Technical
- Relative Strength Index (RSI)
- MODD 52.36
- IMMX 61.41
- Support Level
- MODD $0.97
- IMMX $1.92
- Resistance Level
- MODD $1.15
- IMMX $2.25
- Average True Range (ATR)
- MODD 0.09
- IMMX 0.17
- MACD
- MODD 0.01
- IMMX 0.03
- Stochastic Oscillator
- MODD 50.00
- IMMX 67.61
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.